Research Article
A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
Table 4
Coronary artery abnormalities for patients with Kawasaki disease in 4 groups during 12 months follow-up.
| | Cardiac complications | Acute phase | 1 month | 3 months | 6 months | 12 months |
| | Group 1 () | CALs | 11 (14.3) | 9 (11.7) | 6 (7.8) | 2 (2.6) | 1 (1.3) | | CAAs | 2 (2.6) | 2 (2.6) | 1 (1.3) | 1 (1.3) | — | | GCAAs | 1 (1.3) | 1 (1.3) | 1 (1.3) | — | — | | Group 2 () | CALs | 159 (19.5) | 90 (11.0) | 31 (3.8) | 10 (1.2) | 7 (0.9) | | CAAs | 29 (3.5) | 14 (1.7) | 6 (0.7) | 5 (0.6) | 2 (0.2) | | GCAAs | 3 (0.4) | 2 (0.2) | 2 (0.2) | 1 (0.1) | — | | Group 3 () | CALs | 88 (35.3) | 51 (20.5) | 23 (9.2) | 15 (6.0) | 11 (4.4) | | CAAs | 22 (8.8) | 16 (6.4) | 13 (5.2) | 10 (4.0) | 8 (3.2) | | GCAAs | 2 (0.8) | 2 (0.8) | 3 (1.2) | 3 (1.2) | 3 (1.2) | | Group 4 () | CALs | 81 (58.7) | 56 (40.6) | 38 (27.5) | 29 (21.0) | 20 (14.5) | | CAAs | 42 (30.4) | 30 (21.7) | 21 (15.2) | 20 (14.5) | 13 (9.4) | | GCAAs | 6 (4.3) | 8 (5.8) | 8 (5.8) | 5 (3.6) | 5 (3.6) | | value | CALs | Group 1 vs. 2 | 0.269 | 0.857 | 0.087 | 0.277 | 0.515 | | Group 2 vs. 3 | <0.001 | <0.001 | 0.001 | <0.001 | 0.001 | OR 2.3
95% CI 1.7-3.1 | OR 2.1
95% CI 1.4-3.0 | OR 2.6
95% CI 1.5-4.5 | OR 5.2
95% CI 2.3-11.7 | OR 5.3
95% CI 2.0-13.9 | | CAAs | Group 1 vs. 2 | 0.491 | 0.407 | 0.469 | 0.418 | — | | Group 2 vs. 3 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | OR 2.7
95% CI 1.5-4.7 | OR 3.9
95% CI 1.9-8.2 | OR 7.4
95% CI 2.8-19.8 | OR 6.8
95% CI 2.3-20.1 | OR 13.5
95% CI 2.9-14.1 |
|
|
Expressed as (%). CALs: coronary artery lesions; CAAs: coronary artery aneurysms; GCAAs: giant coronary artery aneurysms. OR: odds ratio. |
